| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetic Retinopathy | 77 | 2025 | 155 | 23.120 |
Why?
|
| Angiogenesis Inhibitors | 102 | 2025 | 206 | 19.460 |
Why?
|
| Macular Edema | 56 | 2025 | 90 | 15.750 |
Why?
|
| Visual Acuity | 105 | 2025 | 817 | 13.080 |
Why?
|
| Wet Macular Degeneration | 36 | 2025 | 39 | 10.950 |
Why?
|
| Ranibizumab | 61 | 2025 | 72 | 10.610 |
Why?
|
| Vascular Endothelial Growth Factor A | 88 | 2025 | 408 | 10.240 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 51 | 2024 | 93 | 9.540 |
Why?
|
| Intravitreal Injections | 99 | 2025 | 146 | 9.200 |
Why?
|
| Macular Degeneration | 31 | 2025 | 115 | 9.100 |
Why?
|
| Recombinant Fusion Proteins | 52 | 2025 | 772 | 8.810 |
Why?
|
| Tomography, Optical Coherence | 85 | 2025 | 522 | 8.560 |
Why?
|
| Fluorescein Angiography | 64 | 2025 | 138 | 6.910 |
Why?
|
| Geographic Atrophy | 15 | 2024 | 20 | 6.430 |
Why?
|
| Retinal Diseases | 18 | 2024 | 172 | 4.960 |
Why?
|
| Macula Lutea | 17 | 2024 | 45 | 4.920 |
Why?
|
| Diabetes Mellitus | 19 | 2024 | 876 | 4.770 |
Why?
|
| Retinal Detachment | 15 | 2023 | 83 | 4.560 |
Why?
|
| Antibodies, Monoclonal, Humanized | 23 | 2024 | 509 | 4.560 |
Why?
|
| Vitrectomy | 25 | 2024 | 108 | 4.420 |
Why?
|
| Retinal Vein Occlusion | 17 | 2022 | 28 | 4.400 |
Why?
|
| Retinal Vessels | 24 | 2024 | 75 | 4.390 |
Why?
|
| Choroidal Neovascularization | 12 | 2023 | 28 | 4.300 |
Why?
|
| Retinal Perforations | 10 | 2024 | 27 | 3.690 |
Why?
|
| Laser Coagulation | 17 | 2023 | 129 | 3.570 |
Why?
|
| Bevacizumab | 20 | 2024 | 64 | 2.980 |
Why?
|
| Retina | 22 | 2023 | 452 | 2.630 |
Why?
|
| Humans | 243 | 2025 | 125466 | 2.170 |
Why?
|
| Scleral Buckling | 9 | 2022 | 13 | 2.130 |
Why?
|
| Choroid | 8 | 2024 | 39 | 2.100 |
Why?
|
| Glucocorticoids | 10 | 2024 | 384 | 2.070 |
Why?
|
| Aged | 92 | 2025 | 19747 | 2.070 |
Why?
|
| Middle Aged | 101 | 2025 | 26833 | 2.040 |
Why?
|
| Endophthalmitis | 7 | 2016 | 77 | 2.010 |
Why?
|
| Follow-Up Studies | 39 | 2025 | 5174 | 1.780 |
Why?
|
| Aged, 80 and over | 47 | 2025 | 6559 | 1.730 |
Why?
|
| Fundus Oculi | 19 | 2025 | 64 | 1.660 |
Why?
|
| Prospective Studies | 47 | 2024 | 6174 | 1.650 |
Why?
|
| Photography | 6 | 2022 | 95 | 1.630 |
Why?
|
| Male | 118 | 2025 | 61637 | 1.590 |
Why?
|
| Peptides, Cyclic | 2 | 2023 | 55 | 1.550 |
Why?
|
| Treatment Outcome | 55 | 2025 | 12305 | 1.550 |
Why?
|
| Female | 123 | 2025 | 66904 | 1.540 |
Why?
|
| Ischemia | 10 | 2021 | 351 | 1.520 |
Why?
|
| Vitreous Detachment | 3 | 2024 | 15 | 1.330 |
Why?
|
| Complement Inactivating Agents | 4 | 2023 | 12 | 1.320 |
Why?
|
| Complement C3 | 4 | 2023 | 48 | 1.270 |
Why?
|
| Retrospective Studies | 55 | 2025 | 16362 | 1.270 |
Why?
|
| Endothelial Growth Factors | 12 | 2023 | 50 | 1.170 |
Why?
|
| Fovea Centralis | 4 | 2020 | 10 | 1.170 |
Why?
|
| Eye Infections, Bacterial | 3 | 2016 | 92 | 1.140 |
Why?
|
| Retinal Vasculitis | 4 | 2023 | 9 | 1.140 |
Why?
|
| Triamcinolone Acetonide | 4 | 2024 | 36 | 1.120 |
Why?
|
| Retinal Pigment Epithelium | 5 | 2024 | 33 | 1.120 |
Why?
|
| Double-Blind Method | 16 | 2025 | 1635 | 1.070 |
Why?
|
| Subretinal Fluid | 7 | 2024 | 11 | 1.070 |
Why?
|
| Nerve Fibers | 3 | 2025 | 75 | 1.000 |
Why?
|
| Retinal Telangiectasis | 3 | 2025 | 5 | 0.990 |
Why?
|
| Epiretinal Membrane | 4 | 2024 | 15 | 0.970 |
Why?
|
| Disease Progression | 14 | 2025 | 2083 | 0.910 |
Why?
|
| Adult | 49 | 2025 | 29642 | 0.910 |
Why?
|
| Fluocinolone Acetonide | 4 | 2020 | 6 | 0.890 |
Why?
|
| Vitreous Body | 5 | 2024 | 106 | 0.850 |
Why?
|
| Cysts | 2 | 2024 | 102 | 0.850 |
Why?
|
| Retinal Vein | 3 | 2022 | 12 | 0.820 |
Why?
|
| Drug Delivery Systems | 3 | 2025 | 188 | 0.820 |
Why?
|
| Ophthalmology | 6 | 2024 | 198 | 0.820 |
Why?
|
| Clinical Trials as Topic | 5 | 2023 | 1104 | 0.810 |
Why?
|
| Angiopoietin-2 | 4 | 2024 | 13 | 0.810 |
Why?
|
| Cataract | 3 | 2022 | 223 | 0.800 |
Why?
|
| Benchmarking | 1 | 2023 | 137 | 0.790 |
Why?
|
| Antibodies, Bispecific | 2 | 2024 | 38 | 0.790 |
Why?
|
| Eye Infections, Fungal | 4 | 2014 | 77 | 0.770 |
Why?
|
| Edema | 2 | 2022 | 137 | 0.740 |
Why?
|
| Carbonic Anhydrases | 11 | 2003 | 26 | 0.720 |
Why?
|
| Neovascularization, Pathologic | 7 | 2018 | 239 | 0.720 |
Why?
|
| Ophthalmic Solutions | 2 | 2011 | 91 | 0.710 |
Why?
|
| Ophthalmoscopy | 3 | 2019 | 28 | 0.710 |
Why?
|
| Vision Disorders | 4 | 2023 | 211 | 0.690 |
Why?
|
| No-Show Patients | 1 | 2020 | 3 | 0.680 |
Why?
|
| Basement Membrane | 5 | 2024 | 48 | 0.680 |
Why?
|
| Vitreoretinal Surgery | 2 | 2021 | 7 | 0.670 |
Why?
|
| Lost to Follow-Up | 1 | 2020 | 33 | 0.670 |
Why?
|
| Retinal Hemorrhage | 2 | 2017 | 23 | 0.660 |
Why?
|
| Cataract Extraction | 3 | 2017 | 216 | 0.660 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2019 | 292 | 0.650 |
Why?
|
| Sensory Thresholds | 1 | 2019 | 35 | 0.640 |
Why?
|
| Postoperative Complications | 4 | 2017 | 3055 | 0.640 |
Why?
|
| Patient Dropouts | 1 | 2019 | 52 | 0.640 |
Why?
|
| Choroid Diseases | 1 | 2019 | 21 | 0.620 |
Why?
|
| Eye Diseases | 2 | 2011 | 117 | 0.610 |
Why?
|
| Monitoring, Physiologic | 1 | 2020 | 377 | 0.580 |
Why?
|
| Microaneurysm | 3 | 2023 | 3 | 0.580 |
Why?
|
| Retinal Degeneration | 3 | 2025 | 93 | 0.560 |
Why?
|
| Lasers | 2 | 2017 | 114 | 0.530 |
Why?
|
| Drug Administration Schedule | 6 | 2022 | 730 | 0.510 |
Why?
|
| Patient Compliance | 1 | 2019 | 472 | 0.510 |
Why?
|
| Lasers, Solid-State | 1 | 2016 | 17 | 0.500 |
Why?
|
| Meningoencephalitis | 1 | 2016 | 17 | 0.500 |
Why?
|
| Retinitis | 1 | 2016 | 18 | 0.500 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2024 | 1119 | 0.490 |
Why?
|
| Anti-Bacterial Agents | 5 | 2019 | 2429 | 0.480 |
Why?
|
| Time Factors | 10 | 2024 | 6323 | 0.480 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2018 | 120 | 0.480 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 118 | 0.480 |
Why?
|
| Vancomycin | 1 | 2017 | 217 | 0.470 |
Why?
|
| Cell Hypoxia | 12 | 2004 | 95 | 0.450 |
Why?
|
| Clinical Protocols | 5 | 2022 | 240 | 0.450 |
Why?
|
| Povidone-Iodine | 2 | 2011 | 10 | 0.450 |
Why?
|
| Injections, Intraocular | 3 | 2024 | 10 | 0.440 |
Why?
|
| West Nile Fever | 1 | 2016 | 139 | 0.430 |
Why?
|
| Retinal Ganglion Cells | 2 | 2025 | 99 | 0.430 |
Why?
|
| Precision Medicine | 2 | 2018 | 321 | 0.420 |
Why?
|
| Cryosurgery | 1 | 2013 | 47 | 0.420 |
Why?
|
| Fungi | 3 | 2014 | 69 | 0.420 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2004 | 240 | 0.420 |
Why?
|
| Atrophy | 6 | 2024 | 231 | 0.410 |
Why?
|
| Uveitis | 2 | 2024 | 36 | 0.400 |
Why?
|
| Biomarkers | 10 | 2024 | 3103 | 0.400 |
Why?
|
| Transcription Factors | 10 | 2004 | 2603 | 0.390 |
Why?
|
| Choroid Neoplasms | 2 | 2013 | 25 | 0.390 |
Why?
|
| Nuclear Proteins | 9 | 2004 | 1284 | 0.390 |
Why?
|
| Vitreoretinopathy, Proliferative | 2 | 2022 | 6 | 0.390 |
Why?
|
| Antisepsis | 1 | 2011 | 8 | 0.380 |
Why?
|
| Mycoses | 2 | 2014 | 118 | 0.380 |
Why?
|
| Bacteria | 2 | 2016 | 481 | 0.370 |
Why?
|
| Eye | 2 | 2024 | 228 | 0.370 |
Why?
|
| Ophthalmologists | 2 | 2024 | 17 | 0.370 |
Why?
|
| Ciliary Body | 1 | 2011 | 31 | 0.360 |
Why?
|
| Retinal Neovascularization | 3 | 2020 | 14 | 0.360 |
Why?
|
| Ubiquitin-Protein Ligases | 3 | 2004 | 359 | 0.360 |
Why?
|
| Surgical Wound Infection | 2 | 2017 | 259 | 0.360 |
Why?
|
| Kidney Neoplasms | 4 | 2004 | 440 | 0.360 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2004 | 472 | 0.360 |
Why?
|
| Algorithms | 6 | 2024 | 1633 | 0.350 |
Why?
|
| Aging | 1 | 2018 | 1182 | 0.350 |
Why?
|
| Uveal Neoplasms | 1 | 2011 | 59 | 0.350 |
Why?
|
| Retreatment | 4 | 2018 | 89 | 0.350 |
Why?
|
| Retinal Drusen | 3 | 2024 | 6 | 0.340 |
Why?
|
| Antibodies, Monoclonal | 3 | 2019 | 1026 | 0.340 |
Why?
|
| Regression Analysis | 3 | 2022 | 781 | 0.340 |
Why?
|
| Surgical Flaps | 2 | 2024 | 203 | 0.340 |
Why?
|
| Hospitals, University | 1 | 2010 | 98 | 0.340 |
Why?
|
| Neoplasm Proteins | 10 | 2004 | 681 | 0.340 |
Why?
|
| Cephalosporins | 1 | 2011 | 137 | 0.330 |
Why?
|
| Regional Blood Flow | 3 | 2019 | 209 | 0.330 |
Why?
|
| Drug Hypersensitivity | 1 | 2011 | 96 | 0.330 |
Why?
|
| Quality of Life | 4 | 2023 | 1949 | 0.320 |
Why?
|
| Pharmaceutical Preparations | 3 | 2023 | 79 | 0.320 |
Why?
|
| Monitoring, Intraoperative | 1 | 2010 | 133 | 0.310 |
Why?
|
| DNA-Binding Proteins | 8 | 2004 | 2061 | 0.310 |
Why?
|
| Cryptococcosis | 1 | 2009 | 42 | 0.310 |
Why?
|
| Oculomotor Nerve | 1 | 2008 | 6 | 0.310 |
Why?
|
| Risk Factors | 11 | 2024 | 10301 | 0.300 |
Why?
|
| Cranial Nerve Neoplasms | 1 | 2008 | 8 | 0.300 |
Why?
|
| Capillary Permeability | 2 | 2020 | 75 | 0.300 |
Why?
|
| Drug Therapy, Combination | 4 | 2025 | 1173 | 0.300 |
Why?
|
| Oculomotor Nerve Diseases | 1 | 2008 | 17 | 0.300 |
Why?
|
| Blindness | 2 | 2021 | 72 | 0.300 |
Why?
|
| Eye Injuries, Penetrating | 1 | 2008 | 19 | 0.300 |
Why?
|
| Rhabdoid Tumor | 1 | 2008 | 53 | 0.290 |
Why?
|
| Exudates and Transudates | 2 | 2021 | 21 | 0.290 |
Why?
|
| Antigens, Neoplasm | 8 | 2003 | 384 | 0.290 |
Why?
|
| Combined Modality Therapy | 8 | 2020 | 1240 | 0.290 |
Why?
|
| Corneal Ulcer | 1 | 2008 | 56 | 0.290 |
Why?
|
| Vitelliform Macular Dystrophy | 2 | 2024 | 2 | 0.280 |
Why?
|
| Single-Blind Method | 2 | 2021 | 241 | 0.280 |
Why?
|
| Teratoma | 1 | 2008 | 126 | 0.280 |
Why?
|
| Cross Infection | 1 | 2010 | 326 | 0.270 |
Why?
|
| Practice Guidelines as Topic | 3 | 2024 | 1272 | 0.270 |
Why?
|
| Young Adult | 7 | 2024 | 9086 | 0.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2002 | 1980 | 0.260 |
Why?
|
| Biomarkers, Tumor | 7 | 2008 | 1534 | 0.240 |
Why?
|
| Gene Expression Profiling | 2 | 2004 | 1756 | 0.240 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 2913 | 0.240 |
Why?
|
| United States | 9 | 2024 | 10926 | 0.240 |
Why?
|
| Cross-Sectional Studies | 7 | 2024 | 3433 | 0.240 |
Why?
|
| Melanoma | 2 | 2013 | 943 | 0.230 |
Why?
|
| Adolescent | 6 | 2024 | 19448 | 0.230 |
Why?
|
| Silicone Oils | 1 | 2024 | 11 | 0.230 |
Why?
|
| Intraocular Pressure | 2 | 2024 | 144 | 0.230 |
Why?
|
| Oxygen | 6 | 2018 | 556 | 0.230 |
Why?
|
| Aqueous Humor | 2 | 2022 | 27 | 0.230 |
Why?
|
| Keratomileusis, Laser In Situ | 1 | 2006 | 148 | 0.230 |
Why?
|
| Angiopoietins | 2 | 2021 | 21 | 0.220 |
Why?
|
| Drug Approval | 1 | 2024 | 43 | 0.220 |
Why?
|
| Myopia | 1 | 2006 | 192 | 0.220 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2002 | 63 | 0.220 |
Why?
|
| Complement C5 | 1 | 2023 | 7 | 0.220 |
Why?
|
| Hypoxia | 4 | 2004 | 248 | 0.220 |
Why?
|
| Cyclin D1 | 1 | 2004 | 113 | 0.220 |
Why?
|
| Tumor Cells, Cultured | 9 | 2004 | 1077 | 0.220 |
Why?
|
| Ligases | 2 | 2000 | 47 | 0.220 |
Why?
|
| Photochemotherapy | 2 | 2022 | 35 | 0.220 |
Why?
|
| United States Food and Drug Administration | 1 | 2024 | 150 | 0.220 |
Why?
|
| Entropy | 1 | 2023 | 26 | 0.220 |
Why?
|
| Meta-Analysis as Topic | 1 | 2024 | 162 | 0.210 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2023 | 6 | 0.210 |
Why?
|
| Evidence-Based Medicine | 2 | 2024 | 631 | 0.210 |
Why?
|
| Traction | 1 | 2022 | 9 | 0.200 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 9 | 2004 | 97 | 0.200 |
Why?
|
| Drug Resistance | 2 | 2013 | 256 | 0.200 |
Why?
|
| Eye Neoplasms | 2 | 2013 | 50 | 0.200 |
Why?
|
| Prone Position | 1 | 2022 | 33 | 0.200 |
Why?
|
| Central Serous Chorioretinopathy | 1 | 2022 | 6 | 0.190 |
Why?
|
| Porphyrins | 1 | 2022 | 17 | 0.190 |
Why?
|
| Hypoxia-Inducible Factor 1 | 8 | 2004 | 18 | 0.190 |
Why?
|
| Delphi Technique | 1 | 2023 | 210 | 0.190 |
Why?
|
| Biomedical Research | 2 | 2019 | 518 | 0.190 |
Why?
|
| Network Meta-Analysis | 1 | 2022 | 28 | 0.190 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2024 | 373 | 0.190 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2012 | 348 | 0.190 |
Why?
|
| Equipment Design | 2 | 2020 | 589 | 0.190 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 1900 | 0.190 |
Why?
|
| Registries | 3 | 2023 | 1434 | 0.180 |
Why?
|
| Confidence Intervals | 1 | 2021 | 283 | 0.180 |
Why?
|
| Postoperative Period | 2 | 2020 | 335 | 0.180 |
Why?
|
| Blood-Retinal Barrier | 2 | 2020 | 3 | 0.180 |
Why?
|
| Drug Implants | 2 | 2020 | 42 | 0.180 |
Why?
|
| Cytokines | 3 | 2022 | 1288 | 0.180 |
Why?
|
| Computer Systems | 1 | 2021 | 37 | 0.180 |
Why?
|
| Cornea | 1 | 2006 | 654 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2020 | 1692 | 0.180 |
Why?
|
| Videoconferencing | 1 | 2020 | 21 | 0.170 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2020 | 57 | 0.170 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 173 | 0.170 |
Why?
|
| Consensus | 1 | 2023 | 644 | 0.170 |
Why?
|
| Fractals | 1 | 2019 | 2 | 0.160 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2019 | 20 | 0.160 |
Why?
|
| Microcirculation | 2 | 2019 | 96 | 0.160 |
Why?
|
| Recurrence | 3 | 2019 | 1394 | 0.160 |
Why?
|
| Biological Products | 1 | 2021 | 123 | 0.160 |
Why?
|
| Congresses as Topic | 1 | 2020 | 175 | 0.160 |
Why?
|
| Income | 1 | 2020 | 134 | 0.160 |
Why?
|
| Longitudinal Studies | 2 | 2022 | 1334 | 0.160 |
Why?
|
| Insurance Coverage | 1 | 2020 | 120 | 0.150 |
Why?
|
| Early Diagnosis | 1 | 2019 | 183 | 0.150 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 511 | 0.150 |
Why?
|
| Antifungal Agents | 3 | 2014 | 291 | 0.150 |
Why?
|
| Delayed-Action Preparations | 1 | 2018 | 109 | 0.150 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 153 | 0.150 |
Why?
|
| Proteins | 2 | 2000 | 1039 | 0.150 |
Why?
|
| Necrosis | 7 | 2004 | 209 | 0.150 |
Why?
|
| Breast Neoplasms | 5 | 2004 | 2519 | 0.150 |
Why?
|
| Visual Prosthesis | 1 | 2017 | 4 | 0.150 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2019 | 102 | 0.140 |
Why?
|
| Vision, Low | 1 | 2017 | 14 | 0.140 |
Why?
|
| Ultrasonography | 3 | 2024 | 939 | 0.140 |
Why?
|
| Retinitis Pigmentosa | 1 | 2017 | 84 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 291 | 0.130 |
Why?
|
| Drug and Narcotic Control | 1 | 2016 | 17 | 0.130 |
Why?
|
| Legislation, Drug | 1 | 2016 | 9 | 0.130 |
Why?
|
| Prosthesis Implantation | 1 | 2017 | 140 | 0.130 |
Why?
|
| Cohort Studies | 6 | 2022 | 4843 | 0.130 |
Why?
|
| Administration, Topical | 1 | 2016 | 138 | 0.130 |
Why?
|
| Beryllium | 1 | 2016 | 3 | 0.130 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2002 | 214 | 0.120 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 426 | 0.120 |
Why?
|
| Lung Neoplasms | 4 | 2012 | 1654 | 0.120 |
Why?
|
| Therapeutic Equivalency | 1 | 2015 | 13 | 0.120 |
Why?
|
| Photoreceptor Cells, Vertebrate | 1 | 2015 | 35 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 362 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 378 | 0.120 |
Why?
|
| Endotamponade | 2 | 2024 | 9 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factors | 3 | 2023 | 50 | 0.110 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 3 | 2004 | 36 | 0.110 |
Why?
|
| Fluconazole | 2 | 2014 | 48 | 0.110 |
Why?
|
| Medication Adherence | 1 | 2018 | 400 | 0.110 |
Why?
|
| Amphotericin B | 2 | 2014 | 90 | 0.110 |
Why?
|
| Electronic Health Records | 1 | 2020 | 724 | 0.100 |
Why?
|
| von Hippel-Lindau Disease | 3 | 2002 | 20 | 0.100 |
Why?
|
| History, 18th Century | 1 | 2013 | 70 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 732 | 0.100 |
Why?
|
| Observational Studies as Topic | 2 | 2023 | 88 | 0.100 |
Why?
|
| Carbonic Anhydrase IX | 8 | 2003 | 12 | 0.100 |
Why?
|
| Telemedicine | 1 | 2018 | 438 | 0.100 |
Why?
|
| Blood Glucose | 1 | 2016 | 1134 | 0.090 |
Why?
|
| Anterior Chamber | 1 | 2012 | 58 | 0.090 |
Why?
|
| Chlorhexidine | 1 | 2011 | 47 | 0.090 |
Why?
|
| Lymphokines | 2 | 2002 | 67 | 0.090 |
Why?
|
| Drug Costs | 1 | 2011 | 61 | 0.090 |
Why?
|
| Age Factors | 1 | 2018 | 2828 | 0.090 |
Why?
|
| Retinopathy of Prematurity | 1 | 2011 | 57 | 0.090 |
Why?
|
| Liver Function Tests | 1 | 2011 | 101 | 0.090 |
Why?
|
| Glucose | 1 | 2015 | 878 | 0.090 |
Why?
|
| Refraction, Ocular | 1 | 2013 | 303 | 0.090 |
Why?
|
| Laser Therapy | 1 | 2013 | 249 | 0.090 |
Why?
|
| Florida | 1 | 2010 | 78 | 0.090 |
Why?
|
| Decision Making | 1 | 2015 | 657 | 0.080 |
Why?
|
| Acute Disease | 2 | 2010 | 1096 | 0.080 |
Why?
|
| Prognosis | 7 | 2024 | 4691 | 0.080 |
Why?
|
| Signal Transduction | 3 | 2021 | 4595 | 0.080 |
Why?
|
| Neoplasms | 2 | 2004 | 2800 | 0.080 |
Why?
|
| Penicillins | 1 | 2011 | 154 | 0.080 |
Why?
|
| Child | 3 | 2024 | 24607 | 0.080 |
Why?
|
| Immunohistochemistry | 6 | 2003 | 1703 | 0.080 |
Why?
|
| Flucytosine | 1 | 2009 | 17 | 0.080 |
Why?
|
| Cryptococcus neoformans | 1 | 2009 | 21 | 0.080 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2021 | 69 | 0.080 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 280 | 0.080 |
Why?
|
| In Situ Hybridization | 4 | 2004 | 472 | 0.080 |
Why?
|
| Intraoperative Complications | 1 | 2010 | 170 | 0.080 |
Why?
|
| Preoperative Care | 1 | 2011 | 353 | 0.080 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2008 | 3 | 0.080 |
Why?
|
| Incidence | 1 | 2016 | 3136 | 0.080 |
Why?
|
| Subarachnoid Space | 1 | 2008 | 24 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 2 | 2008 | 625 | 0.080 |
Why?
|
| Mesencephalon | 1 | 2008 | 39 | 0.080 |
Why?
|
| Eye Enucleation | 1 | 2008 | 54 | 0.070 |
Why?
|
| Keratoplasty, Penetrating | 1 | 2008 | 53 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2001 | 669 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2020 | 2904 | 0.070 |
Why?
|
| Fatal Outcome | 1 | 2008 | 357 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2008 | 338 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2024 | 3310 | 0.070 |
Why?
|
| Blotting, Western | 4 | 2003 | 1109 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 2 | 2001 | 503 | 0.070 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2002 | 550 | 0.070 |
Why?
|
| Body Weights and Measures | 1 | 2006 | 42 | 0.060 |
Why?
|
| Capillaries | 2 | 2017 | 63 | 0.060 |
Why?
|
| Hydrocephalus | 1 | 2008 | 245 | 0.060 |
Why?
|
| Neurosurgical Procedures | 1 | 2008 | 306 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2020 | 1399 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2024 | 3603 | 0.060 |
Why?
|
| Transfection | 3 | 2004 | 1076 | 0.060 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 3 | 2003 | 395 | 0.060 |
Why?
|
| Immunoblotting | 2 | 2004 | 312 | 0.060 |
Why?
|
| Suspensions | 1 | 2024 | 8 | 0.060 |
Why?
|
| Pandemics | 2 | 2023 | 1113 | 0.060 |
Why?
|
| Search Engine | 1 | 2023 | 5 | 0.050 |
Why?
|
| Inflammation | 2 | 2022 | 1446 | 0.050 |
Why?
|
| RNA, Messenger | 4 | 2004 | 2812 | 0.050 |
Why?
|
| Plasmids | 2 | 2004 | 513 | 0.050 |
Why?
|
| Vitreous Hemorrhage | 1 | 2023 | 9 | 0.050 |
Why?
|
| Equivalence Trials as Topic | 1 | 2023 | 12 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2023 | 9 | 0.050 |
Why?
|
| Neurofibromin 2 | 1 | 2022 | 9 | 0.050 |
Why?
|
| Nephrons | 1 | 2002 | 20 | 0.050 |
Why?
|
| Indocyanine Green | 2 | 2015 | 54 | 0.050 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2002 | 24 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2008 | 1156 | 0.050 |
Why?
|
| Syringes | 1 | 2022 | 25 | 0.050 |
Why?
|
| Photosensitizing Agents | 1 | 2022 | 34 | 0.050 |
Why?
|
| Cell Division | 2 | 2001 | 780 | 0.050 |
Why?
|
| Up-Regulation | 2 | 2004 | 875 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2023 | 231 | 0.050 |
Why?
|
| Canada | 1 | 2022 | 286 | 0.050 |
Why?
|
| Pentosan Sulfuric Polyester | 1 | 2021 | 1 | 0.050 |
Why?
|
| Machine Learning | 1 | 2024 | 251 | 0.050 |
Why?
|
| Cell Adhesion Molecule-1 | 1 | 2021 | 1 | 0.050 |
Why?
|
| Monocyte Chemoattractant Proteins | 1 | 2021 | 8 | 0.050 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2021 | 26 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 2057 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 1244 | 0.050 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2021 | 39 | 0.050 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2021 | 38 | 0.050 |
Why?
|
| RNA | 2 | 2004 | 574 | 0.050 |
Why?
|
| Helix-Loop-Helix Motifs | 1 | 2001 | 43 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2002 | 1033 | 0.040 |
Why?
|
| Iatrogenic Disease | 1 | 2021 | 129 | 0.040 |
Why?
|
| Ribonucleases | 1 | 2000 | 52 | 0.040 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2000 | 25 | 0.040 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2001 | 85 | 0.040 |
Why?
|
| Extracellular Space | 1 | 2001 | 87 | 0.040 |
Why?
|
| Organ Size | 1 | 2022 | 441 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2011 | 1316 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 275 | 0.040 |
Why?
|
| Antigens, Nuclear | 1 | 2001 | 61 | 0.040 |
Why?
|
| Slit Lamp Microscopy | 1 | 2020 | 5 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 2001 | 204 | 0.040 |
Why?
|
| Nitroimidazoles | 1 | 2000 | 44 | 0.040 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2002 | 280 | 0.040 |
Why?
|
| Half-Life | 1 | 2020 | 159 | 0.040 |
Why?
|
| Trans-Activators | 2 | 2001 | 801 | 0.040 |
Why?
|
| Observation | 1 | 2020 | 42 | 0.040 |
Why?
|
| Erythropoietin | 1 | 2001 | 106 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2003 | 556 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2001 | 404 | 0.040 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2019 | 62 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2000 | 381 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2000 | 1338 | 0.040 |
Why?
|
| Calcinosis | 1 | 2001 | 180 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2004 | 826 | 0.040 |
Why?
|
| Medicare | 1 | 2023 | 428 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2024 | 688 | 0.040 |
Why?
|
| Breast | 1 | 2001 | 213 | 0.040 |
Why?
|
| Protein Binding | 2 | 2020 | 1755 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2021 | 421 | 0.040 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2020 | 225 | 0.040 |
Why?
|
| Cells | 1 | 1999 | 27 | 0.040 |
Why?
|
| Research Design | 1 | 2023 | 694 | 0.040 |
Why?
|
| Gene Expression Regulation | 4 | 2004 | 2524 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2024 | 647 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2002 | 664 | 0.040 |
Why?
|
| Specialization | 1 | 2019 | 75 | 0.040 |
Why?
|
| Expert Testimony | 1 | 2018 | 37 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2021 | 467 | 0.040 |
Why?
|
| Carcinoma | 1 | 2000 | 290 | 0.040 |
Why?
|
| Anesthetics, Local | 1 | 2019 | 84 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2019 | 283 | 0.040 |
Why?
|
| Models, Genetic | 1 | 2000 | 761 | 0.040 |
Why?
|
| Caveolins | 1 | 1997 | 15 | 0.040 |
Why?
|
| Electroretinography | 1 | 2017 | 115 | 0.040 |
Why?
|
| Multimodal Imaging | 1 | 2018 | 114 | 0.030 |
Why?
|
| Infant | 2 | 2011 | 12601 | 0.030 |
Why?
|
| Emergency Medical Services | 1 | 2021 | 397 | 0.030 |
Why?
|
| European Union | 1 | 2016 | 12 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2021 | 578 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2024 | 2093 | 0.030 |
Why?
|
| Internet | 1 | 2019 | 376 | 0.030 |
Why?
|
| Gene Expression | 1 | 2001 | 1554 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 617 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 824 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2015 | 20 | 0.030 |
Why?
|
| Phenotype | 2 | 2021 | 4269 | 0.030 |
Why?
|
| Voriconazole | 1 | 2014 | 34 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2017 | 668 | 0.030 |
Why?
|
| Survival Analysis | 3 | 2003 | 1494 | 0.030 |
Why?
|
| Logistic Models | 1 | 2019 | 1808 | 0.030 |
Why?
|
| COS Cells | 2 | 2004 | 275 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1997 | 634 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 1997 | 1400 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 261 | 0.030 |
Why?
|
| Visual Fields | 1 | 2014 | 133 | 0.030 |
Why?
|
| Observer Variation | 1 | 2014 | 300 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2000 | 860 | 0.030 |
Why?
|
| Light Coagulation | 1 | 2013 | 24 | 0.030 |
Why?
|
| RNA, Neoplasm | 2 | 2004 | 139 | 0.030 |
Why?
|
| Nevus | 1 | 2013 | 35 | 0.030 |
Why?
|
| Hyperthermia, Induced | 1 | 2013 | 54 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2022 | 14143 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 2 | 2002 | 259 | 0.020 |
Why?
|
| Mass Screening | 1 | 2018 | 785 | 0.020 |
Why?
|
| Hemangioma | 1 | 2013 | 94 | 0.020 |
Why?
|
| Retinoblastoma | 1 | 2013 | 110 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2014 | 364 | 0.020 |
Why?
|
| Retinal Neoplasms | 1 | 2013 | 100 | 0.020 |
Why?
|
| Radiation Injuries | 1 | 2013 | 143 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2012 | 71 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2014 | 798 | 0.020 |
Why?
|
| Enzyme Induction | 2 | 2001 | 104 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2019 | 817 | 0.020 |
Why?
|
| Prevalence | 1 | 2016 | 2469 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 1997 | 1538 | 0.020 |
Why?
|
| Fluorescence | 1 | 2009 | 96 | 0.020 |
Why?
|
| Coloring Agents | 1 | 2009 | 75 | 0.020 |
Why?
|
| Response Elements | 2 | 1999 | 96 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2019 | 1271 | 0.020 |
Why?
|
| Mutation | 1 | 2000 | 5903 | 0.020 |
Why?
|
| Syndrome | 1 | 2009 | 1122 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2004 | 22 | 0.010 |
Why?
|
| Mixed Function Oxygenases | 1 | 2004 | 30 | 0.010 |
Why?
|
| Immune Sera | 1 | 2004 | 95 | 0.010 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2004 | 36 | 0.010 |
Why?
|
| Immediate-Early Proteins | 1 | 2004 | 58 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2004 | 391 | 0.010 |
Why?
|
| Doxycycline | 1 | 2004 | 117 | 0.010 |
Why?
|
| Animals | 5 | 2004 | 34309 | 0.010 |
Why?
|
| Survival | 1 | 2003 | 19 | 0.010 |
Why?
|
| Apoptosis | 2 | 2002 | 1817 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 330 | 0.010 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2002 | 31 | 0.010 |
Why?
|
| RNA Interference | 1 | 2004 | 508 | 0.010 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2002 | 24 | 0.010 |
Why?
|
| RNA Probes | 1 | 2002 | 30 | 0.010 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2002 | 41 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2003 | 232 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2004 | 670 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2002 | 127 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2004 | 1001 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2004 | 691 | 0.010 |
Why?
|
| Thymidine Phosphorylase | 1 | 2001 | 12 | 0.010 |
Why?
|
| Mucin-1 | 1 | 2001 | 35 | 0.010 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2001 | 54 | 0.010 |
Why?
|
| DNA Primers | 1 | 2002 | 657 | 0.010 |
Why?
|
| England | 1 | 2001 | 60 | 0.010 |
Why?
|
| Drug Therapy | 1 | 2001 | 87 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2002 | 331 | 0.010 |
Why?
|
| Nephrectomy | 1 | 2002 | 178 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2001 | 138 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2003 | 491 | 0.010 |
Why?
|
| Mice | 3 | 2004 | 17743 | 0.010 |
Why?
|
| ErbB Receptors | 1 | 2001 | 283 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2002 | 430 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 1293 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2003 | 1430 | 0.010 |
Why?
|
| Cobalt | 1 | 1999 | 18 | 0.010 |
Why?
|
| Iron Chelating Agents | 1 | 1999 | 15 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2001 | 880 | 0.010 |
Why?
|
| Cell Line | 1 | 2004 | 2755 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2002 | 560 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2004 | 1705 | 0.010 |
Why?
|
| Multienzyme Complexes | 1 | 1999 | 89 | 0.010 |
Why?
|
| Cysteine Endopeptidases | 1 | 1999 | 114 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2011 | 8272 | 0.010 |
Why?
|
| Receptor, ErbB-2 | 1 | 2001 | 514 | 0.010 |
Why?
|
| Survival Rate | 1 | 2003 | 2050 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 1999 | 262 | 0.010 |
Why?
|
| Mammals | 1 | 1999 | 257 | 0.010 |
Why?
|
| Genes, fos | 1 | 1997 | 17 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1997 | 121 | 0.010 |
Why?
|
| HeLa Cells | 1 | 1999 | 808 | 0.010 |
Why?
|
| Caveolin 1 | 1 | 1997 | 48 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2002 | 1034 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2001 | 1275 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2001 | 733 | 0.010 |
Why?
|
| Genes, ras | 1 | 1997 | 100 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2001 | 2184 | 0.010 |
Why?
|
| Lung | 1 | 2003 | 1487 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 1997 | 486 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2001 | 1025 | 0.010 |
Why?
|